Kezdőlap・Részvénylista・Novartis AG

Novartis AG

Lezárt

150.55 -0.74

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

150.49

Maximum

151.34

Fő mutatók
By Trading Economics
Bevétel	110M 3.3B
Értékesítés	894M 14B
P/E Szektor átlag	23.649 57.002
Egy részvényre jutó nyereség	2.41
Osztalékhozam	3.02
Profit margin	22.654
Munkavállalók	75,267
EBITDA	526M 5.9B

Ajánlások
By TipRanks
Ajánlások	Semleges
12 hónapos előrejelzés	+5.38% upside

Osztalékok
By Acuity
Osztalékhozam Szektor átlag	3.02% 2.22%

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	13B 298B
Előző nyitás	151.29
Előző zárás	150.55

Novartis AG Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 15. 23:51 UTC

U.S. Industrial Production MoM data set for August 18, 2026, amid mixed economic signals and a forecasted increase of only 0.3%.

2026. aug. 15. 23:51 UTC

Bitcoin is trading roughly flat during Saturday's session, remaining near the lower end of its one-month trading range and below its 20-day moving average.

2026. aug. 15. 23:41 UTC

U.S. equities pull back amid disappointing retail sales and consumer sentiment, while geopolitical tensions and upcoming FOMC Minutes raise concerns for market stability.

2026. aug. 15. 23:41 UTC

European equity and bond markets closed for holiday as U.S. consumer sentiment drops, raising concerns over economic stability ahead of key data releases.

2026. aug. 15. 23:41 UTC

French, Italian, and Spanish markets closed for holiday as U.S. consumer sentiment drops sharply, raising concerns over inflation and potential Federal Reserve rate hikes.

2026. aug. 15. 23:41 UTC

Market Complacency Amidst Bond Volatility: U.S. Stocks Slip as Consumer Sentiment Falls and Retail Sales Decline, While Crypto Shows Resilience.

2026. aug. 15. 23:41 UTC

Cautious Optimism for Stabilization in Canadian Housing Prices Ahead of August 20 Index Release Amid Mixed Economic Signals.

2026. aug. 15. 23:41 UTC

Market Analysts Brace for Philadelphia Fed Manufacturing Index Release Amid Disappointing Retail Sales and Economic Uncertainty.

2026. aug. 15. 23:31 UTC

China's House Price Index YoY release on August 17, 2026, shows cautious optimism as home price declines ease amid mixed economic sentiment and global investor confidence.

2026. aug. 15. 23:11 UTC

Cautious Market Sentiment Ahead of July 2026 Building Permits Data Release, Forecasting 1.37 Million Issued Amid Recent Volatility

2026. aug. 15. 23:11 UTC

Australia's Westpac Consumer Confidence Index set for release amid cautious market sentiment and global economic uncertainties.

2026. aug. 15. 23:01 UTC

Upcoming Housing Starts Data Release on August 18, 2026, Amid Concerns Over Consumer Spending and Inflation Impacting Real Estate Markets.

2026. aug. 15. 23:01 UTC

U.S. Import Prices Expected to Rise 0.1% Amid Positive Inflation Sentiment and Reduced Fed Rate Hike Expectations

2026. aug. 15. 23:01 UTC

U.S. Export Prices Expected to Drop 0.2% Amid Slowing Inflation and Weak Retail Sales, Influencing Fed's Interest Rate Decisions

2026. aug. 15. 23:01 UTC

Market Awaits U.S. Building Permits Data Amid Optimism for Construction Growth and Infrastructure Investments.

2026. aug. 15. 23:01 UTC

U.S. Housing Starts Data for July 2026 Set to Release on August 18, Amid Mixed Market Sentiment and Forecast of 1.35 Million Units

2026. aug. 15. 23:01 UTC

EUR/CAD is trading roughly flat during after-market hours, showing little change since Friday's close and remaining near the lower end of its one-month range.

2026. aug. 15. 22:51 UTC

Australia's Westpac Consumer Confidence Index set for August 18, 2026 release amid global economic uncertainties and mixed market performance.

2026. aug. 15. 22:51 UTC

Canada's July 2026 Housing Starts Data Release Expected at 248K Amid Cautious Market Sentiment and Volatile Trends.

2026. aug. 15. 22:51 UTC

Japan's Core Inflation Rate Expected to Rise to 1.8% YoY Amid Global Economic Pressures and Potential BoJ Interest Rate Hike

2026. aug. 15. 22:51 UTC

Japan's July Exports YoY Data Set for Release Amid Optimistic Market Sentiment and Strong Nikkei Performance.

2026. aug. 15. 22:51 UTC

Japan's July trade balance expected to show a -680 billion yen deficit amid rising import costs and weak yen, while equities gain on Wall Street optimism.

2026. aug. 15. 22:51 UTC

Japan's Inflation Rate Release on August 20 Expected to Impact Monetary Policy and Market Sentiment Amid Anticipated Interest Rate Hikes.

2026. aug. 15. 22:41 UTC

NY Empire State Manufacturing Index Set for Release Amid Caution Over Disappointing Retail Sales and Economic Sentiment.

2026. aug. 15. 22:41 UTC

Canada's Inflation Rate Expected to Rise 0.5% in July Amid Mixed Market Sentiments and External Economic Pressures

2026. aug. 15. 22:41 UTC

MBA 30-Year Mortgage Rate Release on August 19 Expected to Impact Housing Market Amid Cooling Inflation and Interest Rates

2026. aug. 15. 22:41 UTC

Canada's July Inflation Rate Expected to Rise from 2.8% to 3%, Amid Geopolitical Tensions and Supply Chain Disruptions

2026. aug. 15. 22:41 UTC

Canada's Core Inflation Rate Release on August 17, 2026, Sparks Caution Among Investors Amid Geopolitical Tensions and Trade Uncertainty.

2026. aug. 15. 22:41 UTC

Avalanche is trading lower today, with no specific news identified. The asset remains within its one-month range amid shifting investment patterns among younger investors.

2026. aug. 15. 22:32 UTC

Japan's Machinery Orders MoM data set for August 18, 2026, with a forecasted increase of 0.079%, amid positive stock market sentiment and investor confidence in capital spending.

Társak összehasonlítása

Árváltozás

Novartis AG Előrejelzés

Célár

By TipRanks

5.38% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 159 USD 5.38%

Magas 180 USD

Alacsony 139 USD

5 Wall Street elemző 12 hónapos célárain alapulva a(z)Novartis AG termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Semleges

5 ratings

Vétel

Tartás

Eladás

5 Wall Street elemző célárain alapulva a(z)Novartis AG termékhez az elmúlt 3 hónapban.

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.